MiMedx posted a GAAP net loss of $14.84 million, or $0.10 per diluted share, for the quarter ended June 30, 2026.
Net sales fell 34.7% to $64.36 million versus the prior-year quarter.
Surgical net sales rose 15.1% to $39.3 million, while Wound net sales dropped 61.1% to $25.07 million.
Gross margin narrowed 12.1 percentage points to 69.0%.
The company completed a reduction-in-force and other cost actions; it repurchased about $13 million of stock and ended the quarter with $135.8 million in cash.
MDXG•
